Brief: Ultragenyx Announces Phase 3 Aspire Results In Angelman Syndrome
02/09/2026 21:09
BRIEF-Ultragenyx Announces Phase 3 Aspire Results In Angelman Syndrome Sept 2 (Reuters) - Ultragenyx Pharmaceutical Inc. RARE.O:
ULTRAGENYX ANNOUNCES PHASE 3 ASPIRE RESULTS IN ANGELMAN SYNDROME
ULTRAGENYX PHARMACEUTICAL - PHASE 3 ASPIRE STUDY DID NOT ACHIEVE PRIMARY OR KEY SECONDARY ENDPOINTS
ULTRAGENYX PHARMACEUTICAL - SAFETY PROFILE IN ASPIRE STUDY CONSISTENT WITH PHASE 1/2
ULTRAGENYX PHARMACEUTICAL - TO EVALUATE APAZUNERSEN PROGRAM AND IMPLEMENT SIGNIFICANT EXPENSE REDUCTIONS
ULTRAGENYX PHARMACEUTICAL - EXPECTS TO CONTINUE TOWARD PROFITABILITY IN 2027
Source text: ID:nGNX5gyGjV
Further company coverage: RARE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx